Get started with EndoPredict by downloading the provider guide.
Whether you’ve heard about genetic testing before or want to learn more, we can help provide in-depth information on the test and your testing options.
For patients with ER+, HER2-, node negative or node positive breast cancer, EndoPredict provides three individualized results to use to help determine the right breast cancer treatment decisions.
EndoPredict is a next generation prognostic genomic test that predicts individual risk of early and late breast cancer recurrence across years 0-15. By knowing your patient’s individualized absolute chemotherapy benefit and predicted distant recurrence up to 15 years at the time of diagnosis, the EndoPredict test helps you make informed adjuvant treatment decisions for your breast cancer patients.
EndoPredict helps you answer:
What is the chance my patient’s cancer will return within 10 years?
How will their cancer potentially respond to chemotherapy?
Can they safely stop hormone treatment (endocrine therapy) at five years?
EndoPredict is validated in more than 4,000 breast cancer patients with ER+, HER2-, N0 and N1 disease. No other test provides the long-term results and robust benefits of EndoPredict.
The EndoPredict report provides a clear, individualized risk of recurrence for years 0-10 based on a tumor’s specific biology and pathology. Patients will also receive an individualized absolute chemotherapy benefit specific to their tumor. By knowing this information, you’ll know your patient’s risk of recurrence at 5-15 years and whether they might safely forego extended endocrine therapy.
EndoPredict better identifies a large percentage of low-risk patients (average of 6% recurrence).1,2,3
More than 70% of N0 patients3,4
Up to 30% of N+ patients3,4
Provider completes the test request form (in the portal or via paper TRF)
Myriad’s laboratory processing staff contacts your pathology partner to directly obtain the tumor sample.
Results are sent to the ordering provider (in the portal or via mail)
Every EndoPredict test provides actionable results to guide treatment decisions, including a specific score that indicates whether your patient’s cancer is at a low or high risk of returning within the next 10 years.
Myriad is committed to providing patients with access to accurate and affordable genetic results through extensive coverage with most insurance plans and financial assistance programs.
Myriad believes in providing the most accurate and highest quality tests for patients. From hereditary cancer to precision medicine, our tests are designed to give providers and patients the most accurate answer possible.